HORA PDE6B

Drug Profile

HORA PDE6B

Alternative Names: HORA-PDE6B

Latest Information Update: 25 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Horama
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinitis pigmentosa
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Retinitis pigmentosa

Most Recent Events

  • 19 Sep 2017 Preclinical trials in Retinitis pigmentosa in France (Intraocular) prior to September 2017
  • 19 Sep 2017 Horama plans a phase I/II trial for Retinitis pigmentosa (In children, In adolescents, In adults) in France in 2017 (EudraCT-2016-001429-16)
  • 19 Jun 2013 HORA PDE6B receives Orphan Drug status for Retinitis pigmentosa in European Union (Register of designated Orphan Medicinal Products by European Commission, September 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top